Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Are you completely MENTAL. there is no news.

<< Previous

Bullboard Posts

Next >>

Comment by PTBaileyon Sep 15, 2021 5:56pm

116 Views

Post# 33866264

RE:RE:RE:Are you completely MENTAL. there is no news.

Dude51 wrote: Sorry folks but I cashed out couple of weeks ago. Had enough with there BS. Its just one thing after another and I see that has not changed.

Hope you didn't take a big loss. I am going to stick around for the long haul. A lot of frustration I know, seems like one step forward two back. But I don't want to regret getting out just before things start to happen. So either going to lose it all or gain in the end. Best of luck to you.

<< Previous

Bullboard Posts

Next >>

Golden Minerals closes Yoquivo gold-silver project sale